A number of genomics companies have made Technology Review's list of smart companies.
Separate studies in NEJM from Regeneron Pharmaceuticals and Ionis Pharmaceuticals target the ANGPTL3 gene in an effort to develop heart disease treatments.
Biotech and academic leaders met with Trump administration officials to discuss NIH funding, ScienceInsider reports.
The firms will have exclusive access for a limited time to the data from the first 50,000 individuals with samples in the biobank to be sequenced.
The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.
Indivumed will provide Regeneron with tissue samples and related data for use in its cancer research programs.
The DiscovEHR study, conducted by the Regeneron Genetics Center and the Geisinger Health System, uncovered many associations between genetic variants and clinical phenotypes.
The Children's National team will return diagnostic results to patients and Regeneron will use the genomic data in its drug development pipeline.
Pittsburgh-based Curable is building a coalition to sequence genomes of patients with a rare autoimmune disease of the bile ducts to inform drug development.
Mount Sinai is the latest healthcare provider to link up with Regeneron's Genetics Center, to pair NGS data with electronic medical record data.
New results from the NASA Twins Study indicate that the immune system may rev up when in space, the Washington Post reports.
Kelvin Droegemeier, the new science advisor, spoke at the American Association for the Advancement of Science meeting, Geekwire reports.
In PNAS this week: whole-genome assembly for the white shark, paper-based microfluidic method for detecting the malaria parasite, and more.
The World Health Organization has announced the members of its gene-editing committee, according to NPR.